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Spinal opioid-induced itch, a prevalent side effect
of pain management, has been proposed to result
from pain inhibition. We now report that the m-opioid
receptor (MOR) isoform MOR1D is essential for
morphine-induced scratching (MIS), whereas the
isoformMOR1 is required only for morphine-induced
analgesia (MIA). MOR1D heterodimerizes with
gastrin-releasing peptide receptor (GRPR) in the
spinal cord, relaying itch information. We show that
morphine triggers internalization of both GRPR and
MOR1D, whereas GRP specifically triggers GRPR in-
ternalization and morphine-independent scratching.
Providing potential insight into opioid-induced itch
prevention,we demonstrate thatmolecular and phar-
macologic inhibition of PLCb3 and IP3R3, down-
stream effectors of GRPR, specifically block MIS
but not MIA. In addition, blocking MOR1D-GRPR
association attenuates MIS but not MIA. Together,
these data suggest that opioid-induced itch is an
active process concomitant with but independent
of opioid analgesia, occurring via the unidirectional
cross-activation of GRPR signaling byMOR1D heter-
odimerization.INTRODUCTION
Itch and pain are two fundamental sensory perceptions evoked
by distinct external inputs. They are encoded and transmitted
by primary nociceptive fibers and varying subpopulations of
dorsal horn neurons (Davidson and Giesler, 2010; Patel and
Dong, 2010). The ability to discriminate between itch and painallows animals to employ the proper motor response (scratching
versus withdrawal) so that potentially damaging stimuli from the
environment can be avoided. Intriguingly, it has been well docu-
mented that itch and pain may counteract each other under
some conditions. Indeed a wide range of noxious stimuli
including thermal, mechanical, chemical, and electrical stimuli
are able to inhibit itch (Ikoma et al., 2006). Conversely, it is widely
assumed that itch may be unmasked by pain reduction, and one
of the most cited examples of this antagonistic relationship is
opioid-induced itch, or pruritus (Davidson and Giesler, 2010;
Ikoma et al., 2006; Paus et al., 2006). In fact, pruritus is one of
the most prevalent acute side effects of the spinal or epidural
use of opioids in patients who undergo pain treatment or in those
who receive cesarean section (Ballantyne et al., 1988; Chaney,
1995; Hales, 1980), which has hampered the use of opioids as
an analgesic to their full extent. The most influential theory
offered to explain the antagonism of itch and pain is perhaps
the ‘‘occlusion’’ or selectivity hypothesis, which stipulates that
pruriceptors are part of nociceptors and that inactivation of the
pain signaling centrally is a prerequisite for activation of the
itch signaling (Carstens, 1997; McMahon and Koltzenburg,
1992). The occlusion hypothesis has gained more support from
an analysis of mutant mice lacking vesicular glutamate trans-
porter 2 in subsets of dorsal root ganglia (DRG) neurons that dis-
played attenuated pain but enhanced itch (Lagerstro¨m et al.,
2010; Liu et al., 2010). In the spinal cord, all spinothalamic track
neurons in primates recorded to be responsive to capsaicin also
responded to pruritic stimuli (Davidson et al., 2007). In addition,
ablation of dorsal horn neurons expressing neurokinin 1 receptor
attenuated both pain and itch in rats (Carstens et al., 2010; Nich-
ols et al., 1999). Mice lacking neurons expressing gastrin-
releasing peptide receptor (GRPR), a molecular signature for
the putative itch-specific labeled line in the spinal cord, nearly
eliminate their scratching response to a range of pruritic stimuli
without altering normal nociceptive transmission (Sun and
Chen, 2007; Sun et al., 2009). Conversely, mice lacking a subsetCell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc. 447
of neurons expressing transcription factor Bhlhb5 during devel-
opment display enhanced spontaneous scratching behavior, but
their pain behavior is not reduced (Ross et al., 2010), suggesting
that removal of pain signaling is not a prerequisite for induction of
itch and that the central itch signaling can be induced indepen-
dently of nociceptive transmission. Collectively, convincing
evidence in support of the ‘‘occlusion’’ theory in the spinal
cord is lacking.
Opioid-induced itch has been suggested to be mediated
primarily through the m-opioid receptor (MOR), a key receptor
for opiates (Kieffer, 1999). Intrathecal (i.t.) injection of morphine,
a prototypical opiate agonist, produces dose-dependent
scratching behavior (Ko and Naughton, 2000; Kuraishi et al.,
2000). Consistently opioid antagonists have been found to
reduce itch and concomitantly attenuate the analgesic effects
of opiates (Ballantyne et al., 1988; Ko et al., 2004). MOR1 is acti-
vated by exogenous morphine without rapid internalization in
several cell types including dorsal horn neurons (Alvarez et al.,
2002; Keith et al., 1996; Trafton et al., 2000). Activation of
MOR1 primarily inhibits adenylyl cyclase and the cAMP/PKA
signaling pathway (Law et al., 2000). As opioid-induced itch is
most notable and severe when opioids are intrathecally applied,
one tantalizing hypothesis is that opioids evoke itch sensation by
activating GRPR signaling. The present study was designed to
test this hypothesis and to determine whether activation of the
itch signaling is due to a removal of pain inhibition.
RESULTS
Morphine-Induced Scratching Occurs Independent
of Morphine-Induced Analgesia
To examine whether morphine-induced scratching (MIS) and
morphine-induced analgesia (MIA) are correlated to each other,
we studied the dose-response curve and time course of MIS
and MIA after i.t. injection of morphine and found that both MIA
and MIS increased in a dose-dependent manner (Figure 1A).
However, when the morphine dose increased from 0.3 to
1.0 nmol, the MIA effect was enhanced by 81%, whereas MIS
only had a slight increase. In addition, time course analysis at
0.3 nmol of morphine revealed obvious segregation of MIA and
MIS (Figure 1B). After i.t. morphine, MIS increased dramatically
within 10min and quickly decreased. In contrast,MIAmaintained
at a maximal level for at least 1 hr. To further examine whether
opioid-induced itch is due to pain inhibition, we employed
a morphine tolerance paradigm in which the degree of tolerance
to morphine is measured by the latency of tail-flick (analgesic
effect) (Fairbanks and Wilcox, 1999). If pain inhibition unmasks
itch, MIS would be attenuated in mice with morphine tolerance.
Twenty-four hours after morphine pretreatment, tail-flick laten-
cies of mice returned to their baseline (Figure 1C). As expected,
mice pretreatedwithmorphine developedmorphine tolerance as
measured by a significant reduction of MIA relative to the saline
control (Figure 1D). To our surprise, despite reduced analgesic
effect, MIS did not differ between the two groups (Figure 1E).
Separation of MIS from MIA was also examined by a chronic
morphine tolerance model. Tail immersion assay showed gradu-
ally reduced amplitude ofMIA during the 5 days of induction (Fig-
ure 1F), and morphine tolerance was evident on the 6th day (Fig-448 Cell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc.ure 1G). Again, there was not a significant difference of MIS
between the control and tolerant mice (Figure 1H). Therefore,
MIS occurs irrespective of the degree of MIA, indicating that
MIS and MIA are mediated by distinct mechanisms.
MOR1D Is an Itch-Specific Receptor
The finding that MIS is separable fromMIA prompted us to study
the molecular basis of disassociation of MIS andMIA. Mice lack-
ing the Oprm gene displayed loss of MIA (Loh et al., 1998;
Matthes et al., 1996; Sora et al., 1997). MIS was nearly abolished
in mice lacking the coding exons 2 and 3 of the Oprm gene (Loh
et al., 1998), whereas GRP-induced scratching (GIS) was not
affected (Figure 2A). Consistent with previous studies (Ballan-
tyne et al., 1988; Ko et al., 2004), MIS was also abolished by
naloxone, a nonspecificMOR antagonist (Figure 2B). In contrast,
neither naloxone (see Figure S1A available online) nor beta-FNA
(Figure S1B) impacted GIS. The mouse Oprm gene encodes 16
coding exons, comprising dozens of spliced isoforms that
primarily differ at C terminus (Pan, 2005; Pasternak, 2010). For
example, MOR1 consists of exons 14, whereas MOR1D of
exons 13 and 89 (Figure 2C). The multiplicity of theOprm iso-
form system has been suggested to underlie the heterogeneity
and variability of analgesic and scratching effects exerted by
different agonists (Andoh et al., 2008; Pasternak, 2004; Ravin-
dranathan et al., 2009). We postulated that different isoforms
of MOR are responsible for MIS and MIA, respectively. To test
this, we performed an exon-specific siRNA knockdown experi-
ment in the spinal cord of mice followed by examining the effect
of knockdown onMIS. Knockdown of either exon 1 contained by
the majority of MOR isoforms including MOR1, or exon 9 con-
tained by isoforms 1C, 1D, and 1E significantly attenuated MIS
(Figure 2D). However, siRNA knockdown of exon 4 contained
by MOR1 or exon 7 contained by 1C and 1E failed to reduce
MIS significantly (Figure 2D). Interestingly, knockdown of exon
1 or 4 markedly attenuated MIA, whereas knockdown of exon
7 or 9 had no effect on MIA (Figure 2E). Quantitative RT-PCR
tests confirmed that spinal MOR1 mRNA was selectively
decreased by exon 1 or exon 4 siRNA (Figures 2F and 2G),
and spinal MOR1D mRNA was significantly reduced after exon
1 or exon 9 siRNA treatment (Figures 2F and 2H). In contrast,
neither MOR1 nor MOR1D expression in DRG neurons was
compromised by siRNA treatments (Figures S1C and S1D).
The knockdown of MOR1D protein in spinal cord by exon 9
siRNA was verified by western blot (Figures 2I and 2J), whereas
MOR1 and GRPR protein level was not affected. To further
exclude the possibility that exon 9 siRNA treatment might affect
GRPR function, we examined i.t. GIS, and found no significant
reduction of GIS after MOR isoform knockdown (Figure S1E).
These results indicate that exon 9 is critical for MIS but not for
MIA, whereas exon 4 is critical for MIA but not for MIS. Thus,
spinal MOR1D has emerged as a MIS-specific isoform, whereas
MOR1 possesses MIA-specific function.
Colocalization of GRPR and MOR1D in the Dorsal Horn
of the Spinal Cord
To determine the expression pattern of MOR1D, we used the
strategy previously described (Abbadie et al., 2000) to generate
an antibody specifically against a unique MOR1D C terminus.
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Figure 1. MIS Is Not Correlated with MIA
(A) Dose effect of i.t. morphine on MIS and MIA in 30 min.
(B) Time course of morphine on MIS and MIA.
(C) Induction of acuteMIA tolerance with morphine (100mg/kg, s.c.) or saline. Mice returned to the basal nociceptive latencies 24 hr after themorphine treatment.
(D) Acute MIA tolerance was tested with i.t. morphine 24 hr after morphine pretreatment. *p < 0.05.
(E) i.t. morphine induced comparable scratches in acute tolerant mice and control mice.
(F) Induction of chronic MIA tolerance by daily injection of morphine (10 mg/kg, s.c.) or saline for 5 days and MIA tolerance was examined daily.
(G) After 5 days of systemic morphine injection, i.t. morphine also showed antinociceptive tolerance. *p < 0.05.
(H) i.t. morphine induced comparable scratches in chronic MIA tolerant mice and control mice.
In all experiments, the dose of i.t. morphine is 0.3 nmol. n = 6–8 per group. Error bars represent SEM. s.c., subcutaneous injection.MOR1D and MOR1 antibodies specifically recognized human
embryonic kidney 293 (HEK293) cells transfected with either
MOR1D or MOR1, respectively (Figure S2B), and no cross-
activity was observed between the two antibodies. These data
validate the specificity of MOR1D antibody. Immunostaining
using MOR1D antibody indicates that MOR1D is expressed
mainly in lamina I of the spinal cord (Figures 3A, 3E, and S2A),
and no stainingwasobserved in the spinal cord ofMORknockout
(KO) mice (Figure S2A). In contrast, MOR1 staining is largely
restricted to lamina II with a few in lamina I (Figures 3B and 3H).
Importantly, no colocalization of MOR1 and MOR1D was de-
tected (Figure 3C).
We next examined whether the expression of MOR1D and
GRPR overlaps. Double-staining of MOR1D and GRPR revealed
that the expression of the two receptors overlaps in lamina I cells(Figures 3D–3F). In 25 sections across the lumbar spinal cord,
approximately 31% of GRPR+ cells were costained with
MOR1D, and approximately 65% of MOR1D+ cells with GRPR.
No overlapping expression between GRPR and MOR1 was ob-
served (Figures 3G–3I). Together these data suggest that
MOR1D and GRPR may function together in MIS.
Opioid-Induced Scratching Was Abolished by the
Blockade of the GRPR Function in the Spinal Cord
To examine whether GRPR is important for mediating opioid-
induced itch, we compared MIS between GRPR KO and wild-
type mice. Strikingly, MIS was nearly abolished in GRPR KO
mice (Figure 4A). In contrast, no significant difference in MIA
was observed between the groups (Figure 4B). The abolition of
MIS in GRPR KO mice was recapitulated when an MOR agonistCell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc. 449
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Figure 2. Identification of MIA- and MIS-Specific
MOR Isoforms
(A) MIS was severely impaired in MOR KO mice, whereas
GIS in MOR KO mice was comparable to that in wild-type
littermate control mice. *p < 0.05.
(B) MIS was significantly reduced by naloxone (3 mg/kg,
s.c.). *p < 0.05.
(C) Schematic representation of partial alternative MOR
splicing in the mouse. Clear rectangles represent the
targeting exons by siRNA.
(D) MIS was significantly reduced byMOR siRNA targeting
at exon 1 (MOR1, 1C, 1D, and 1E) and exon 9 (MOR1C, 1D,
and 1E), but not by siRNA targeting at exon 4 (MOR1) or
exon 7 (MOR1C and 1E). *p < 0.05. Sequences of siRNAs
are included in Extended Experimental Procedures.
(E) MOR siRNA targeting at exon 1 and exon 4, but not
exon 7 or exon 9 significantly reduced MIA. *p < 0.05.
(F) Representative gel images showing decreased spinal
MOR1 mRNA level after exon 1- and exon 4-specific
siRNA treatments and decreased spinal MOR1D mRNA
level after exon 1- and exon 9-specific siRNA treatments.
18S RNA, an internal control, was comparable among all
groups.
(G) Exon 1- and exon 4-specific siRNA significantly
knocked downMOR1mRNA in spinal cord as detected by
q-RT-PCR. *p < 0.05.
(H) Spinal MOR1D mRNA level was significantly reduced
by siRNA specific to MOR exon 1 and exon 9 as detected
by qRT-PCR. *p < 0.05.
(I and J)Western blot (I) and quantified data (J) showed that
MOR exon 9 siRNA specifically reduced protein level of
MOR1D but not that of MOR1 or GRPR in the spinal cord.
*p < 0.05.
In all experiments, n = 5–8 per group. Error bars represent
SEM. See also Figure S1.(DAMGO or fentanyl) was intrathecally injected (Figures 4C
and 4E). Analgesic effects did not differ between GRPR KO
mice and their littermate controls after DAMGO or fentanyl treat-
ment (Figures 4D and 4F). Consistently, i.t. injection of a GRPR
antagonist dramatically inhibited MIS (Figure 4G), whereas MIA
remained unchanged (Figures 4H and S3A). These findings
demonstrate that GRPR is required for MIS but not for antinoci-
ceptive transmission. Importantly, the GRPR antagonist itself
has no significant effect on acute pain as tested by tail immersion
assay (Figure S3B) and von Frey (Figure S3C). Therefore, GRPR
is essential for mediating opioid-induced itch, but not for opioid-
mediated antinociception.
Heterodimerization and Cointernalization of MOR1D
and GRPR
The coexpression of GRPRandMOR1D, alongwith their require-
ment for MIS, prompted us to ask whether GRPR and MOR1D
may physically interact through receptor heterodimerization,
a mechanism commonly employed by G protein-coupled recep-
tors (GPCRs) to increase their diverse pharmacological and
physiological properties (Bouvier, 2001; Milligan, 2009). Coim-
munoprecipitation (co-IP) was performed using extracts of
HEK293 cells stably expressing Myc-tagged GRPR together
with HA-tagged MOR1D or HA-tagged MOR1. Myc-GRPR,
when coexpressed with HA-MOR1D, was precipitated by anti-450 Cell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc.HA antibody (Figure 5A, L4). Conversely, precipitation with anti-
Myc antibody identified a band corresponding to HA-MOR1D
in cells coexpressing GRPR and MOR1D (Figure 5B, L4). This
physical interaction is specific to MOR1D because HA-MOR1
and Myc-GRPR were not able to coprecipitate (Figures 5A and
5B, L3). To examine the physical interaction of MOR1D and
GRPR in vivo, we performed co-IP experiments using the spinal
cord membrane preparation. GRPR coprecipitated with MOR1D
by anti-MOR1D antibody (Figure 5C, L3), but not by anti-MOR1
antibody (Figure 5C, L4) or an irrelevant rabbit IgG (Figure 5C,
L2). Together these results indicate that physical interactions
between GRPR and MOR1D exist both in vitro and in vivo.
To test whether MOR1D may cross-activate GRPR and inter-
nalize with GRPR in response to morphine, we first examined
internalization of Myc-tagged GRPR in HEK293 cells stably ex-
pressing either MOR1D and GRPR or MOR1 and GRPR after
morphine stimulation. Morphine failed to induce GRPR internal-
ization in cells expressing GRPR alone (Figures 5D and 5E) or in
cells coexpressing MOR1 and GRPR (Figures 5F and 5G). In
contrast, GRPR internalization was significantly enhanced in
HEK293 cells coexpressing MOR1D and GRPR (Figures 5F
and 5G). Consistent with a previous study (Whistler et al.,
1999), no internalization of HA-MOR1 by morphine was found,
regardless of whether cells express MOR1 only (Figures 5D
and 5E) or coexpress GRPR (Figures 5F and 5G). However, cells
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Figure 3. Coexpression of GRPR and MOR1D in
Lamina I of the Spinal Cord
(A–C) Double immunostaining revealed no colocalization
of MOR1D (red, lamina I) andMOR1 (green, lamina II) in the
spinal cord.
(D–F) Double immunostaining of GRPR (red) and MOR1D
(green) in lamina I of the spinal cord. Arrows indicate co-
expression (yellow) and arrowheads indicate singular
expression. Cells coexpressingGRPR (11/33) andMOR1D
(11/17), which represent approximately 31% of GRPR-
positive cells and approximately 65% of MOR1D-positive
cells respectively, were found in 25 lumbar spinal cord
sections.
(G–I) Double immunostaining revealed no colocalization of
GRPR (red, lamina I) and MOR1 (green, lamina II) in the
dorsal spinal cord.
Scale bar, 50 mm. See also Figure S2.expressing MOR1D (Figures 5D and 5E) or MOR1D and GRPR
(Figures 5F and 5G) showed significant MOR1D internalization
in response tomorphine. Both MOR1 andMOR1Dwere internal-
ized in the presence of DAMGO, regardless of whether GRPR
was present (Figure S4). These results suggest that the coexis-
tence of GRPR andMOR1D is a prerequisite for morphine-medi-
ated GRPR internalization.
Next, we assessed whether naloxone would affect morphine-
induced MOR1D-GRPR internalization. Naloxone inhibited
morphine-induced GRPR or MOR1D internalization in a dose-
dependent manner and at a dose of 10 mM could nearly abolish
MOR1D-GRPR internalization (Figure 5H). Interestingly, the
GRPR antagonist inhibited morphine-induced internalization of
GRPR but not MOR1D (Figure 5I). Consistently, GRP was able
to internalize GRPR, regardless of whether GRPR was coex-
pressed with MOR1D or MOR1 (Figures 5D–5G). However,
neither MOR1D nor MOR1 internalized upon GRP stimulation,
regardless of whether they were coexpressed with GRPR (Fig-
ures 5D–5G). Taken together, these results indicate that despite
coexpression of MOR1D and GRPR, they cannot be reciprocally
activated; only MOR1D is able to cross-activate GRPR in
response to morphine, not vice versa.
Cross-Activation of the GRPR Signaling Transduction
Pathway by MOR1D upon Morphine Stimulation
GRPR can activate multiple signaling pathways, including the
phospholipase C (PLC)/inositol 1,4, 5-trisphosphate (IP3)/Ca2+
signaling pathway, in response to GRPR agonists in a number
of heterologous cell lines (Jensen et al., 2008; Kroog et al.,
1995). To ascertain whether GRPR-dependent calcium re-
sponse might be cross-activated by morphine, we examined
Ca2+ signals in HEK293 cells expressing various combinations
of MOR1, MOR1D, and GRPR. Both morphine and GRP induced
calcium spikes in cells coexpressing MOR1D and GRPR (Fig-Cell 147, 44ure 6A), suggesting an activation of GRPR by
morphine or GRP. Morphine- or GRP-induced
calcium signals were not affected in calcium-
free extracellular buffer, indicating the endo-
plasmic reticulum origin of the calcium (Fig-
ure S5A). However, morphine failed to evokeCa2+ spikes in cells coexpressing MOR1 and GRPR or in cells
containing only GRPR; neither morphine nor GRP generated
a calcium response in cells expressing MOR1D alone
(Figure 6A).
To ascertain whether morphine-induced calcium spike is
a consequence of a cross-activation of GRPR, we pretreated
cells coexpressing MOR1D and GRPR with a GRPR antagonist
or naloxone. Morphine-induced calcium spike was blocked by
the GRPR antagonist and naloxone (Figure 6B). GRP-induced
calcium spikes were completely blocked by the GRPR antag-
onist and significantly reduced by naloxone (Figures 6B and
6D). Both morphine- and GRP-evoked Ca2+ increase were
blocked by U73122 (a selective PLC inhibitor that prevents IP3
liberation) or 2-APB (an IP3 receptor [IP3R] antagonist), whereas
U73343 (an inactive structural analog control for U73122) had
no effect on calcium response to morphine or GRP (Figure 6C).
These data suggest that morphine cross-activates GRPR
through MOR1D as well as the PLC/IP3/Ca2+ signaling pathway.
Coexpression of PLCb Isoforms, IP3R3, and GRPR
in the Spinal Cord
A prerequisite for PLC and IP3R signaling molecules to act
downstream of GRPR is that they are coexpressed in GRPR+
cells. To circumvent the difficulties of double-staining each indi-
vidual PLC and IP3R isoform with GRPR, we took advantage of
mice whose GRPR neurons+ can be ablated specifically in the
spinal cord by bombesin-saporin treatment (Sun et al., 2009)
and used qRT-PCR to compare the mRNA change of individual
isoforms in the superficial dorsal horn betweenmice treated with
bombesin-saporin and with blank-saporin. As confirmed by the
significant decrease of GRPR mRNA (Figure S5B), there was
a complete loss of PLCb3 expression and a significant de-
crease of PLCb1, IP3R type 3 (IP3R3), and MOR1D mRNA in
bombesin-saporin-treated tissues as compared to the control7–458, October 14, 2011 ª2011 Elsevier Inc. 451
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Figure 4. GRPR Is Important for Opioid-Induced Scratching
Behavior
(A) MIS was nearly abolished in GRPR KO mice compared with wild-type
littermate mice. *p < 0.05.
(B) MIA was comparable between GRPR KO and wild-type littermates.
(C) Scratching behavior induced by i.t. DAMGO (0.02 nmol) was significantly
reduced in GRPR KO mice. *p < 0.05.
(D) Analgesic effect of i.t. DAMGO was comparable between GRPR KO and
wild-type littermates.
(E and F) Scratching behavior induced by i.t. fentanyl was significantly
reduced in GRPRKOmice (E), whereas the analgesic effect of fentanyl was not
affected (F). *p < 0.05.
(G) MIS was significantly inhibited by coinjection with the GRPR antagonist
(0.1, 1 nmol). *p < 0.05.
(H) MIA was not significantly affected by coinjection of the GRPR antagonist
(1.0 nmol).
In all experiments, the dose of i.t. morphine is 0.3 nmol. n = 69 per group.
Error bars represent SEM of the mean. See also Figure S3.(Figures 6E, 6F, and S5B). These results reveal coexpression of
PLCb1/3, IP3R3, MOR1D, and GRPR.
Inhibition of PLC/IP3 Signaling Significantly Attenuates
MIS but Not MIA
To determine the physiological relevance of morphine-induced
signaling transduction in vivo, a spinal siRNA knockdown452 Cell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc.approach was employed to investigate whether PLC/IP3 sig-
naling is important for MIS. Consistently, siRNA knockdown of
PLCb1/3 and IP3R3 in mice compromised MIS (Figure 6G). In
contrast, the same treatments did not alter MIA (Figure 6H).
The efficiency and selectivity of siRNA were determined by
qRT-PCR. Spinal PLCb and IP3R3 mRNA level was sig-
nificantly knocked down by approximately 62% and 33%,
respectively (Figure 6I). No significant knockdown of the PLCb
and IP3R3 mRNA in DRG neurons was observed (Figures S5C
and S5D). The reduction of PLCb3 and IP3R3 protein levels in
spinal cord was further confirmed by western blot (Figures S5E
and S5F). Interestingly, i.t. injection of both U73122 and 2-APB
significantly attenuated MIS but had no impact on MIA (Figures
6J and 6K), suggesting an existence of MIS-specific PLC/IP3
signaling in vivo.
MOR1D C Terminus Is Critical for MIS and MOR1D
and GRPR Heterodimeric Interaction
The difference between MOR1 and MOR1D isoforms lies in
a motif consisting of seven amino acids (RNEEPSS) in MOR1D
C terminus (Figure 7A). This motif is likely to be essential for
MOR1D and GRPR physical interaction. To test this, a Tat-fusion
peptide (Tat-MOR1DCT) containing a Tat (YGRKKRRQRRR),
a trans-activating domain of HIV protein that can permeate the
cell membrane (Schwarze et al., 1999), and the RNEEPSS motif
was synthesized (Figure 7A) and injected into the spinal cord.
Introduction of Tat-MOR1DCT permits its competition with
MOR1D for physical contacts with GRPR in vivo. Remarkably,
i.t. injection of Tat-MOR1DCT specifically blocked MIS (Fig-
ure 7B), while leaving GIS (Figure 7B) and MIA (Figure 7C) unper-
turbed. Subsequent co-IP analysis using the membrane
extracts of the spinal cord injected with Tat-MOR1DCT and the
control peptide revealed that Tat-MOR1DCT significantly re-
duced the amount of GRPR precipitated by MOR1D antibody
relative to the control (Figures 7D and 7E). These results demon-
strate that MOR1D C terminus is critical for MOR1D-GRPR
dimerization and MIS.
DISCUSSION
In this study, we present molecular, cellular, biochemical, and
behavioral data that demonstrate uncoupling of opioid-induced
itch and opioid-induced antinociception in the spinal cord.
MOR1D is an identified MOR isoform that does not possess
the cardinal function of an opioid receptor. These data argue
against the prevailing view that opioid induces itch as result of
pain inhibition and uncover that opioid-induced itch is an active
process, independently initiated byMOR1D-mediated activation
of GRPR. Coupled with the finding that MIA remains unaffected
in GRPR KOmice, the present studies further support the notion
that GRPR is an itch-specific receptor (Sun and Chen, 2007) and
GRPR-expressing neurons represent a labeled line for itch in the
spinal cord (Sun et al., 2009).
Unidirectional Cross-Activation of GRPR by MOR1D
through Heterodimeric Interactions
GRP is an itch-specific peptide that is presumably released from
primary afferents to activate spinal GRPR in response to pruritic
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Figure 5. Coimmunoprecipitation and Cointernali-
zation of GRPR and MOR1D
(A) Myc-GRPR (43 kDa) was detected in membrane frac-
tion of MOR1/GRPR cells (L1) and MOR1D/GRPR cells
(L2). Anti-HA antibody coprecipitated Myc-GRPR from
MOR1D/GRPR cells (L4), but not from MOR1/GRPR
cells (L3).
(B) Expression of HA-MOR1 (44 kDa) in HA-MOR1/Myc-
GRPR cells (L1) and expression of HA-MOR1D (44 kDa) in
HA-MOR1D/Myc-GRPR cells (L2) were revealed by anti-
HA immunoblotting. An HA-MOR1D band (44 kDa) was
precipitated by anti-Myc antibody from HA-MOR1D/Myc-
GRPR cells (L4). Anti-Myc antibody failed to precipitate
HA-MOR1 from cells expressing both Myc-GRPR and HA-
MOR1 (L3). IP: immunoprecipitaion, IB: immunoblotting,
kDa: kilodalton.
(C) GRPR, MOR1D, and MOR1 were detected in the
membrane extract of dorsal horn (L1). GRPR was copre-
cipitated by anti-MOR1D (L3) but not by anti-MOR1 (L4)
or irrelevant IgG (L2).
(D and E) Immunostaining (D) and ELISA (E) revealed
endocytosis of HA-MOR1D but not HA-MOR1 or Myc-
GRPR upon morphine treatment, whereas GRP induced
endocytosis of GRPR but not MOR1D or MOR1.
(F and G) Immunostaining (F) and ELISA (G) revealed that
Myc-GRPR, when coexpressed with HA-MOR1D but not
HA-MOR1, internalized upon morphine stimulation. GRP
only induced internalization of GRPP but not MOR1D
or MOR1.
(H) Naloxone dose-dependently blocked morphine-
induced internalization of Myc-GRPR and HA-MOR1D.
(I) The GRPR antagonist blocked morphine-induced
internalization of Myc-GRPR, but not HA-MOR1D.
Data are expressed as mean and standard error of three
independent experiments. Error bars represent SEM.
*p < 0.05. See also Figure S4.stimuli (Sun and Chen, 2007). Spinal morphine may promote
presynaptic release of GRP to activate central GRPR signaling.
However, our studies suggest that GRP is dispensable for
morphine-induced activation of GRPR, and activation of GRPR
in response to morphine is mediated via a postsynaptic mecha-
nism. Indeed,MOR1D andGRPR dimers are detectable by co-IP
in heterologous cells, and MOR1D and GRPR can also be coim-
munoprecipitated from spinal cord membrane preparation.
Thus, spinal opiates produce itch through MOR1D and GRPR
heterodimerization. Importantly, in vivo interference with Tat-
MOR1DCT markedly reduces co-IP of GRPR and MOR1D and
blunts MIS. Taken together, these data demonstrate the impor-
tance of physical interactions between MOR1D and GRPR
in MIS.
Calcium imaging studies illustrate that neither GRPR nor
MOR1D alone are able to elicit a calcium response to morphine.Cell 147, 44Strikingly, a blockade of PLCb and IP3R abol-
ished morphine-induced calcium signaling in
cells coexpressing MOR1D and GRPR. These
results are in accord with previous observations
that the ability of the Gi-coupled receptors
to evoke calcium signaling often depends on
a concomitant activation of the Gq-coupled
receptors (Samways and Henderson, 2006).Distinguished from previous studies, the present study provides
behavioral relevance for the PLCb/IP3-dependent Ca2+ signaling
evoked by morphine. Interestingly, PLCb3 in DRG neurons has
been shown to be required for MIA (Xie et al., 1999) as well as
for histaminergic itch (Han et al., 2006). The fact that spinal
opioid-induced itch is histamine independent (Ko et al., 2004),
along with our finding that no change of PLCb and IP3R occurs
in DRG neurons by siRNA knockdown, indicates that the canon-
ical PLCb/IP3R3/Ca2+ signal transduction pathway in the spinal
cord is itch specific and is different from its function in DRG
neurons.
GPCR heterodimerization synergistically modulates respec-
tive receptor activity, resulting in either enhanced or inhibited
ligand-binding properties or conferring novel function not origi-
nally possessed by the singular receptors (George et al., 2000;
Jordan and Devi, 1999; Lopez and Salome´, 2009). In contrast7–458, October 14, 2011 ª2011 Elsevier Inc. 453
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Figure 6. Cross-Activation of the GRPR Signal Transduction Pathway by MOR1D in Response to Morphine
The responses of HEK293 cells expressing vary receptors to morphine or GRP were tested using calcium imaging.
(A) HEK293 cells coexpressing MOR1D and GRPR showed calcium response to both morphine and GRP. Cells coexpressing MOR1 and GRPR were unable to
respond to morphine, whereas they responded to GRP.
(B) The GRPR antagonist completely blocked morphine and GRP-induced Ca2+ increase in cells coexpressing MOR1D and GRPR. Naloxone blocked morphine-
and reduced GRP-induced Ca2+ response in cells coexpressing MOR1D and GRPR.
(C) Both PLC inhibitor U73122 and IP3 receptor antagonist 2-APB blocked the response tomorphine and GRP in cells coexpressingMOR1D andGRPR. U73343,
an inactive structural analog of U73122, had no effect on morphine- or GRP- evoked Ca2+ increase.
(D) Quantified data comparing peak intracellular calcium concentration. Naloxone significantly reduced GRP-induced [Ca2+]i increase in cells coexpressing
MOR1D and GRPR. n = 3, *p < 0.05.
(E and F) GRPR+ cells in superficial dorsal horn were ablated by bombesin-saporin. The superficial dorsal horn was dissected for qRT-PCR. Gel image (E) and
quantitative analysis (F) showed that PLCb3 mRNA was lost in bombesin-saporin-treated group. PLCb1 and IP3R3 mRNA were significantly decreased by
bombesin-saporin treatment.
(G) Two days after the last injection of PLCb siRNA or IP3R3 siRNA, MIS was significantly reduced. *p < 0.05.
(H) MIA was not significantly affected by PLCb siRNA or IP3R3 siRNA.
(I) PLCb mRNA and IP3R3 mRNA level in the superficial dorsal horn was significantly reduced by i.t. injection of PLCb siRNA and IP3R3 siRNA, respectively.
*p < 0.05.
(J) I.t. MIS was significantly inhibited by U73122, a PLC inhibitor, or 2-APB, an IP3R antagonist. *p < 0.05.
(K) Analgesic effect of i.t. morphine was not significantly affected by U73122 or 2-APB.
In all experiments, n = 67 per group. Error bars represent SEM. See also Figure S5.to reciprocal regulation of each receptor by respective agonists
commonly found in GPCR heterodimerization, which allows for
coincidental detection, our results uncover a unidirectional
signaling model for GPCR crosstalk: whereas morphine-en-
coded itch information is transmitted from MOR1D to GRPR,
GRP-encoded itch signaling cannot be reversely relayed to
MOR1D by GRPR. Interestingly, the observation that a
MOR1D-GRPR coimmunoprecipitated band from spinal cord
membrane preparation is detected in the absence of morphine
stimulation indicates a constitutive presence of MOR1D-GRPR
heterodimeric assembly in vivo. How can GRPR be activated
and internalized by morphine via MOR1D, whereas MOR1D454 Cell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc.cannot be internalized by GRP? One can envision that MOR1D
and GRPR heterodimers may exist in a relatively unstable and
dynamic equilibrium state that can be either strengthened/acti-
vated uponmorphine stimulation, resulting in a cointernalization,
or weakened in response to GRP, leading to a dissociation of
heterodimers so that only GRPR internalizes. This is reminiscent
of agonist-dependent dimerization and internalization of the
d-opioid receptor (Cvejic and Devi, 1997) and may also explain
why the GRPR antagonist blocks morphine-mediated GRPR
but not MOR1D endocytosis. Such a unidirectional signaling
may ensure that opioid-encoded itch information is correctly
relayed to the GRPR-signaling machinery and avoid accidental
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Figure 7. MOR1D C Terminus Is Critical for MIS and MOR1D/GRPR
Dimerization
(A) Sequence comparison of MOR1D and MOR1 reveals a unique motif
in MOR1D C terminus. Synthesized peptide Tat-MOR1DCT contains a Tat
domain from human immunodeficiency virus-type 1 and the motif from
MOR1DCT. Control peptide contains Tat domain and scrambled sequence of
MOR1DCT.
(B) Tat-MOR1DCT blocked MIS without affecting GIS. *p < 0.05.
(C) Tat-MOR1DCT had no effect on MIA. *p < 0.05.
(D and E) Co-IP by anti-MOR1D (D) and quantified O.D. ratio of GRPR and
MOR1D (E) showing Tat-MOR1DCT decreased GRPR/MOR1D interaction in
the lumbar spinal cord.
In all experiments, n = 68 per group. Error bars represent SEM.engagement of MOR1D that may result in inappropriate signal-
ing in a condition when GRPR is activated by GRP released
from primary afferents. This one-way communication mecha-
nism allows for added versatility to the physiological significance
for GPCR heterodimerization and enables opioid receptors to
carry out an unorthodox function.
Why has such amechanism evolved to permit cross-activation
of itch signaling by opioids? One plausible explanation is that
opioid-induced pruritus may serve as the body’s warning sign
for opiate overdose or for internal metabolism disorders. For
example, patients with cholestasis often suffer from terrible
pruritus, which has been attributable to enhanced endogenous
opioidergic signaling that is centrally mediated because opiate
antagonists could ameliorate cholestasic itch, along with several
other systemic itch conditions (Bergasa, 2005; Jones and Ber-
gasa, 1990; Metze et al., 1999).
Our study cannot exclude this possibility that MOR1D may
additionally regulate GRPR signaling through the Gi-coupled
intracellular crosstalks. In this regard, MIS provides a reliable,
unique, and unparalleled behavioral paradigm for facilitatingfurther dissection of detailed intracellular signaling mechanisms
of MOR1D and GRPR interactions and for understanding the
corresponding physiological relevance.Uncoupling of Itch and Pain: Therapeutic Implications
The identification of itch-specific MOR1Dmay shed light into the
physiological and therapeutic relevance of the multiplicity of the
MOR system. Although opiate antagonistsmay be used clinically
to ameliorate spinal opioid-induced itch, their undiscriminating
actions on both MOR1D and MOR1 might hinder opioid anal-
gesia (Szarvas et al., 2003). Our finding, which uncouples MIS
and MIA, enables us to envisage new therapeutic strategies.
Pharmacological or antibody disruption of GPCR heterodimeri-
zation may be a highly cell type-specific targeting approach
(Agnati et al., 2003; Hipser et al., 2010; Waldhoer et al., 2005),
and the unique C terminus of MOR1D may be one of the best
therapeutic targets. This heterodimeric-specific approach would
not perturb the normal function of GRPR or MOR1D in other
tissues where they are singularly expressed and where their
physiological function may be important. Likewise, if MOR1D-
GRPR signaling were involved in cholestatic itch, such a specific
blockade may overcome side effects such as withdrawal-like
symptoms often associated with the use of opioid antagonists
in cholestatic itch (Bergasa, 2005). The present study implies
that the physiological significance of multiple MOR isoforms
may go beyond their normal antinociception paradigm that has
been primarily restricted to the heterogeneity of opioid analgesia
and patients (Pasternak, 2010). Although the disassociation of
centrally mediated MIA from the nonneural tissue-mediated
side effects of opioids has been reported (Ling et al., 1989; Man-
ara et al., 1986), it is muchmore difficult to separate MIA from the
side effect originating centrally. In this regard, an interesting
question arises as to whether MOR1D may mediate other types
of opiate side effects, as it is expressed in other brain areas such
as the nucleus of the solitary tract, where no colocalization with
MOR1 has been found (Abbadie et al., 2000). The uncoupling of
MIA and MIS underscores the necessity of elucidating the func-
tion of individual MOR isoforms, which may promise novel pain
therapy without debilitating side effects.EXPERIMENTAL PROCEDURES
Animals
Generation and genotyping of GRPR KO and MOR KO were described
previously (Hampton et al., 1998; Loh et al., 1998). All the experiments were
performed in accordance with the guidelines of the National Institutes of
Health and were approved by the Animal Studies Committee at Washington
University School of Medicine.
Drugs and Reagents
Morphine, DAMGO, fentanyl, GRP, naloxone, bombesin-saporin (Advanced
Targeting), the GRPR antagonist (D-Phe-6-Bn(6-13)OMe), U73122, U73343,
2-APB, siRNA (Sigma), Tat-MOR1DCT, and sequence-scrambled control
peptide were administered intrathecally.
Behavior
Scratching behavior and tail immersion assay were performed as previously
described (Sun and Chen, 2007). Morphine antinociceptive tolerance was
induced as described (Fairbanks and Wilcox, 1999) (Zhao et al., 2007).Cell 147, 447–458, October 14, 2011 ª2011 Elsevier Inc. 455
Preparation and Intrathecal Injection of siRNA
Selective siRNA duplexes for mouse Oprm exons, PLCb1/3, and IP3R3 were
intrathecally injected daily for 3 consecutive days. Behavior testing and tissue
harvest were carried out at 48 hr after the last injection.
Laser Capture Microdissection
Laser capture microdissection (LCM) were performed as previously described
(van Baarlen et al., 2009), and laminae I and II of the spinal cord were dissected
using the Pix-Cell II with HS caps (Arcturus).
Quantitative RT-PCR
RNAwas isolated from the LCM sample caps using the PicoPure RNA isolation
kit (Arcturus). qRT-PCR amplification was performed using an Mx3000 QPCR
system (Stratagene). All samples were run in triplicate.
Generation of MOR1D Antibody and Immunohistochemistry
Rabbit anti-MOR1D antibody was generated as described (Abbadie et al.,
2000). Double-staining was performed using standard protocols.
Cell Culture and Transfections
To generate lines coexpressingMyc-tagged GRPR and HA-taggedMOR1D or
MOR1 receptors, the cells were subjected to G418/hygromycin double selec-
tion. Clones expressingMyc-GRPR, HA-MOR1, HA-MOR1D, HA-MOR1/Myc-
GRPR, and HA-MOR1D/Myc-GRPR were examined using quantitative
western blot analysis to ensure that clones coexpress GRPR and MOR in
1:1 ratio.
Coimmunoprecipitation and Western Blot Analysis
HEK293 cells expressingMOR1D/GRPR orMOR1/GRPRwere exposed to the
crosslinking agent dithiobis-(succinimidylpropionate) (Pierce) and subse-
quently lysed as described (Koch et al., 2001). The receptor proteins were
incubated with HA antibody (BD bioscience), or c-Myc antibody (Covance).
The complex was precipitated, deglycosylated and separated on SDS gels
(Invitrogen). Proteins were incubated with c-Myc antibody or HA antibody first,
and then with goat horseradish peroxidase-linked secondary antibodies
(Santa Cruz). Immunoblots were developed with the enhanced chemilumines-
cence reagents (Amersham).
Internalization Assays
The receptor internalization assay was performed as described previously
(Pfeiffer et al., 2002).
Calcium Imaging
The cells were loaded with Fura 2-acetomethoxy ester (Molecular Probes) for
ratiometric studies. Cells were imaged at 340 and 380 nm excitation to detect
intracellular free calcium. Each experiment was done in triplicate, and at least
50 cells were analyzed each time.
Statistical Analysis
Statistical comparisons were performed with two-way analysis of variance
(ANOVA) or Student’s t test. All data were expressed as the mean ± standard
error of the mean (SEM) and error bars represent SEM. p < 0.05 was consid-
ered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2011.08.043.
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